🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "major milestone" in the battle against superbug strains of the pathogen, according to researchers.

A Global Public Health Issue

Gonorrhoea infections are increasing worldwide, with data suggesting in excess of 82 million new cases per year. Especially elevated rates are seen in the African continent and nations within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an important and timely step in the face of rising global incidence, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Medical experts are increasingly worried about the rise in treatment-resistant strains. The World Health Organization has designated it as a "critical concern". A tracking program showed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Drugs Receive Clearance

Zoliflodacin, alternatively called a brand name, was cleared by the American regulatory agency in December for use against gonorrhoea. This infection can lead to major issues, including infertility. Scientists hope that focused deployment of this new drug will help slow the spread of drug resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in close succession. This treatment, which is employed against UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

This new treatment emerged from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to develop it.

“This authorization marks a significant shift in the treatment of superbug gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Testing Results and Global Access

According to data released by a prominent scientific publication, zoliflodacin eradicated the vast majority of cases of the STI. This establishes an comparable level with the typical regimen, which uses an injection and a pill. The trial included nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the rights to license and sell the drug in numerous regions with limited resources.

Doctors on the front lines have voiced positive views. Having a one-pill regimen such as this is seen as a "revolutionary step" for managing the epidemic. This is deemed crucial to lessen the impact of the infection for patients and to halt the transmission of extremely resistant gonorrhoea around the world.